Introduction
A new observational study suggests people taking GLP-1 weight loss and diabetes drugs may face slightly higher rates of osteoporosis and gout over time. The research, led by Dr. John Horneff at the University of Pennsylvania, analyzed medical records from a large group of adults with obesity and Type 2 diabetes. While the findings do not prove the drugs cause these conditions, they add to growing interest in how rapid weight loss and reduced appetite may affect bone health and uric acid levels.
What the Researchers Studied
The study reviewed five years of medical records from more than 146,000 adults diagnosed with both obesity and Type 2 diabetes. Researchers compared outcomes in patients using GLP-1 medications with outcomes in similar patients who were not using GLP-1s. The records did not consistently specify which GLP-1 each person took, though documented drugs included semaglutide and liraglutide.
Osteoporosis and Osteomalacia Signals
Osteoporosis weakens bones and raises fracture risk, sometimes after minor falls. In the study, about 4% of GLP-1 users developed osteoporosis compared with a little over 3% of nonusers, which the researchers described as roughly a 30% relative increase. A related condition, osteomalacia, which involves bone softening, was uncommon but appeared about twice as often among GLP-1 users.
Experts not involved in the research noted that weight loss itself can reduce bone density. A key open question is whether the bone changes seen with GLP-1 use reflect expected skeletal adaptation during weight loss or a faster, potentially more concerning loss than would normally be expected.
Gout Risk Appears Modestly Higher
Gout is a painful arthritis caused by elevated uric acid. The study found gout rates of 7.4% among GLP-1 users versus 6.6% among nonusers, about a 12% relative increase. The authors suggested one plausible contributor is rapid weight loss, which can temporarily raise uric acid and trigger gout flares in some people.
Why This Might Be Happening
The study team raised two main possibilities for bone effects. First, because GLP-1 drugs suppress appetite, some patients may consume fewer bone-supporting nutrients such as calcium, vitamin D, and adequate protein. Second, a large and rapid reduction in body weight may change how the body maintains bone, because the skeleton adapts to a lower mechanical load.
Because the study is observational, it cannot establish cause and effect. The dataset also lacked detailed information on diet, exercise, supplement use, and other factors that strongly influence bone density and gout risk.
What Clinicians Say Patients Can Do
Some clinicians emphasize that even if risks rise slightly, patients are not powerless. Structured resistance training and regular activity may help protect bone density during weight loss, and nutrition planning can support adequate protein and micronutrient intake. Clinicians also stress that improved joint pain from weight loss does not necessarily mean improved bone density, so monitoring may still be appropriate for higher-risk patients.
Conclusion
This large record-based study suggests GLP-1 users with obesity and Type 2 diabetes may have somewhat higher rates of osteoporosis and gout over five years, but the findings do not prove the medications are the direct cause. The results reinforce a practical takeaway: when GLP-1 therapy leads to substantial weight loss, patients may benefit from nutrition support, strength-focused exercise, and bone health awareness, especially if they have additional osteoporosis risk factors.
